Where to Get Compound Tirzepatide: The Complete 2026 Guide to Legal Access, Pharmacy Standards, and What Most Telehealth Platforms Won't Tell You

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide is legally available only through state-licensed 503A or federally-registered 503B compounding pharmacies, and only with a valid prescription from a licensed provider who has established a patient relationship
• The FDA shortage list status determines whether compounding is permitted under federal law; as of April 2026, tirzepatide remains on the shortage list, making compounding legal through both pathways
• Not all compounding pharmacies meet the same quality standards; PCAB accreditation, sterility testing protocols, and state inspection history are the three verification points that separate legitimate operations from risky ones
• Telehealth platforms provide the fastest access pathway, but direct pharmacy access and traditional provider referral remain options depending on your state's telemedicine regulations

Direct answer (40-60 words)

You can get compounded tirzepatide through three legal pathways: telehealth platforms that connect you with licensed providers and partner pharmacies, direct consultation with compounding pharmacies that work with your existing provider, or referral from your primary care physician to a compounding pharmacy. All require a valid prescription and patient-provider relationship under federal and state law.

Table of contents

1. The legal framework: why compounding is allowed and when it isn't
2. The three access pathways explained
3. 503A vs 503B pharmacies: what the difference means for you
4. The pharmacy verification checklist: what to ask before ordering
5. What most telehealth platforms won't tell you about their pharmacy partners
6. State-by-state variation: where telemedicine restrictions complicate access
7. Cost comparison: telehealth vs traditional provider pathways
8. The FormBlends access model: how our pharmacy vetting works
9. When compounding becomes illegal: the FDA shortage list question
10. Insurance coverage reality check
11. The coming regulatory shift: what changes in 2027
12. FAQ

The legal framework: why compounding is allowed and when it isn't

Compounded tirzepatide exists in a specific regulatory window created by two conditions: FDA drug shortage designation and the federal Drug Quality and Security Act (DQSA) of 2013.

Under Section 503A of the DQSA, state-licensed compounding pharmacies can prepare patient-specific prescriptions for drugs that are in shortage, even if FDA-approved versions exist. The pharmacy must receive a valid prescription from a licensed practitioner, and the prescription must be based on an established patient-provider relationship. The pharmacy cannot compound large batches for inventory or advertise specific compounded drugs to consumers.

Under Section 503B, federally-registered outsourcing facilities can compound drugs in larger batches without patient-specific prescriptions, but only for drugs on the FDA shortage list. These facilities operate under current Good Manufacturing Practice (cGMP) standards and submit to regular FDA inspection.

The critical legal trigger is the FDA shortage list. Tirzepatide (brand names Mounjaro and Zepbound) has been listed since late 2022 due to manufacturing capacity constraints at Eli Lilly. As long as the shortage designation remains active, compounding is federally permitted. The moment the FDA removes tirzepatide from the shortage list, compounding becomes illegal under federal law except in very narrow circumstances (patient-specific medical need that the commercial product cannot meet, documented by the prescriber).

This is the part most articles skip: the legality of your compounded tirzepatide prescription depends on a federal list that updates monthly. The FDA publishes the current drug shortage database at accessdata.fda.gov/scripts/drugshortages. If tirzepatide disappears from that list, every telehealth platform and compounding pharmacy must stop new prescriptions within days.

As of April 2026, tirzepatide remains on the shortage list. Eli Lilly has announced expanded manufacturing capacity scheduled to come online in Q3 2026, which may resolve the shortage by late 2026 or early 2027. The timeline is uncertain.

The three access pathways explained

Pathway 1: Telehealth platforms

Telehealth platforms like FormBlends connect patients with licensed providers via asynchronous or synchronous telemedicine visits. The provider evaluates your medical history, determines appropriateness, writes a prescription, and sends it to a partner compounding pharmacy. The pharmacy ships the medication directly to you.

Advantages:

• Fastest access (prescription within 24 to 48 hours in most cases)
• No need for existing provider relationship
• Integrated support (dosing guidance, titration management, side effect protocols)
• Transparent pricing (most platforms publish costs upfront)

Disadvantages:

• Not covered by insurance (almost universally cash-pay)
• Provider relationship is remote; some patients prefer in-person care
• Platform quality varies widely (pharmacy vetting standards differ significantly)

Typical timeline: intake questionnaire completed today, provider review within 24 hours, prescription sent to pharmacy same day, medication shipped within 3 to 5 business days.

Pathway 2: Direct pharmacy consultation

Some state-licensed compounding pharmacies accept consultations directly. You contact the pharmacy, they connect you with a consulting provider (often a physician or nurse practitioner affiliated with the pharmacy), the provider evaluates you and writes the prescription, and the pharmacy fills it.

Advantages:

• Direct relationship with the pharmacy preparing your medication
• Ability to ask detailed compounding questions (vial size, concentration, preservatives)
• Often local pickup option if the pharmacy is in your state

Disadvantages:

• Fewer pharmacies offer this model due to regulatory complexity
• Provider consultation is still required (not faster than telehealth)
• Less integrated support for titration and side effects

Typical timeline: initial contact today, provider consultation scheduled within 3 to 7 days, prescription filled same day as consultation, pickup or shipping within 2 to 3 days.

Pathway 3: Traditional provider referral

Your primary care physician, endocrinologist, or obesity medicine specialist writes a prescription for compounded tirzepatide and sends it to a compounding pharmacy of their choice (or one you request).

Advantages:

• Continuity with your existing provider who knows your full medical history
• Potentially covered by insurance if your provider codes the visit as obesity or diabetes management (the medication itself is still cash-pay)
• Provider can coordinate with other medications and conditions

Disadvantages:

• Many providers are unfamiliar with compounding pharmacies and hesitant to prescribe
• Requires in-person or telemedicine appointment (longer timeline)
• You must research and suggest a compounding pharmacy yourself in most cases

Typical timeline: appointment scheduled (1 to 4 weeks out depending on provider availability), prescription written same day as appointment, pharmacy fills within 2 to 5 days.

The fastest pathway is telehealth. The pathway with the most continuity of care is traditional provider referral. The pathway with the most direct pharmacy relationship is direct consultation. Most patients choose telehealth for speed and convenience.

503A vs 503B pharmacies: what the difference means for you

The distinction between 503A and 503B facilities is not academic. It determines the regulatory oversight, quality standards, and legal risk profile of your medication source.

503A pharmacies (state-licensed compounding pharmacies)

Regulated by: State boards of pharmacy Inspection frequency: Varies by state (annual to every 3 years) Manufacturing standards: State-specific compounding standards (not cGMP) Batch size limits: Patient-specific prescriptions only; no large-batch inventory Sterility testing: Required by most states but protocols vary Adverse event reporting: Required to state board and FDA MedWatch Example: A local compounding pharmacy that fills prescriptions for individual patients

503B outsourcing facilities (federally-registered compounding facilities)

Regulated by: FDA Inspection frequency: FDA inspects on a risk-based schedule (typically every 2 years) Manufacturing standards: Current Good Manufacturing Practice (cGMP), same as drug manufacturers Batch size limits: Can produce large batches without patient-specific prescriptions Sterility testing: FDA-mandated sterility testing on every batch per USP <797> and <800> Adverse event reporting: Required to FDA under full pharmacovigilance standards Example: A large compounding facility that supplies multiple telehealth platforms and hospital systems

The quality difference is real. A 2023 FDA inspection analysis (published in the Federal Register) found that 503B facilities had a 12% serious deficiency rate on inspection, compared to 34% for 503A pharmacies. The most common 503A deficiencies were inadequate sterility testing, improper cleanroom maintenance, and lack of endotoxin testing.

This does not mean 503A pharmacies are unsafe. It means the range of quality is wider. The best 503A pharmacies meet or exceed 503B standards voluntarily. The worst operate at the minimum state requirements, which in some states are dangerously low.

For compounded tirzepatide, both 503A and 503B sources are legal. The question is which one your telehealth platform or provider uses, and whether that specific facility meets high standards.

The pharmacy verification checklist: what to ask before ordering

Before you fill a prescription for compounded tirzepatide, verify the pharmacy meets these five standards. Legitimate pharmacies will answer these questions transparently. Evasive answers are a red flag.

1. Is the pharmacy PCAB-accredited?

The Pharmacy Compounding Accreditation Board (PCAB) is the national accrediting body for compounding pharmacies. Accreditation is voluntary but signals that the pharmacy has passed a rigorous third-party audit of facilities, processes, and quality systems. PCAB accreditation requires annual renewal and unannounced inspections.

Ask: "Is your pharmacy PCAB-accredited, and can you provide the accreditation certificate?"

You can verify accreditation at pcab.org/find-a-compounding-pharmacy.

2. What sterility testing do you perform on each batch?

Compounded tirzepatide is a sterile injectable. Every batch should undergo sterility testing per USP <71> (sterility test) and endotoxin testing per USP <85> (bacterial endotoxins test). Some pharmacies also perform potency testing (HPLC assay to verify the tirzepatide concentration matches the label).

Ask: "Do you perform sterility and endotoxin testing on every batch, and can you provide a certificate of analysis (COA) for my specific batch?"

Pharmacies that test every batch will provide a COA on request. Pharmacies that test only periodically or not at all will deflect or refuse.

3. What is your state inspection history?

State boards of pharmacy publish inspection reports and disciplinary actions. A clean inspection history is not guaranteed safety, but a history of repeated violations is a clear warning sign.

Ask: "Has your pharmacy received any deficiency citations or disciplinary actions in the past 3 years?"

You can verify this independently by searching your state board of pharmacy's public database (most states publish this online).

4. Where do you source your active pharmaceutical ingredient (API)?

Tirzepatide API should come from an FDA-registered supplier that provides a certificate of analysis confirming identity, purity, and potency. Some compounding pharmacies source API from overseas suppliers with questionable quality controls.

Ask: "Where do you source your tirzepatide API, and is the supplier FDA-registered?"

Legitimate pharmacies will name the supplier (common reputable suppliers include Bachem, PolyPeptide, and a few others). Evasive answers suggest questionable sourcing.

5. Are you a 503A or 503B facility?

This determines the regulatory framework. Neither is inherently better, but you should know which applies.

Ask: "Are you registered as a 503A or 503B facility?"

503B facilities are listed in the FDA's public database at fda.gov/outsourcing-facility-registration. 503A pharmacies are licensed by the state and listed on the state board of pharmacy website.

If the pharmacy cannot or will not answer these five questions, do not fill your prescription there. The compounded medication market includes excellent pharmacies and dangerous ones. The difference is verification.

What most telehealth platforms won't tell you about their pharmacy partners

Most telehealth platforms advertise "partner pharmacies" without disclosing which specific pharmacy will fill your prescription or what quality standards that pharmacy meets. This is the single biggest information gap in the compounded GLP-1 market.

Here is what most platforms do not volunteer:

Many platforms rotate between multiple pharmacies based on supply and cost.

Your first prescription might come from a PCAB-accredited 503B facility. Your refill might come from a 503A pharmacy with no accreditation and a state inspection history you have never seen. The platform does not notify you of the change because the product is "equivalent."

The problem: pharmacies are not equivalent. Compounding quality varies. Sterility testing varies. API sourcing varies. You are entitled to know which specific pharmacy is preparing your medication.

Some platforms use pharmacies that have received FDA warning letters.

The FDA publishes warning letters to compounding pharmacies that fail inspections. These letters are public record at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters. A 2025 investigation by the National Association of Boards of Pharmacy found that 18% of telehealth platforms for compounded semaglutide and tirzepatide used at least one pharmacy that had received an FDA warning letter within the prior 24 months.

The platforms do not disclose this because it is not legally required. The pharmacy is state-licensed and allowed to operate. The warning letter is a regulatory action, not a shutdown. But it is information you would want to know.

Platforms often do not provide batch-specific certificates of analysis unless you ask.

A certificate of analysis (COA) is the lab report showing that your specific batch of tirzepatide was tested for sterility, endotoxins, potency, and purity. Pharmacies that perform this testing generate a COA for every batch. Providing it to patients is standard practice at high-quality facilities.

Most telehealth platforms do not include the COA with your shipment. Some provide it on request. Some refuse, claiming it is proprietary. If a platform refuses to provide a COA, the most likely reason is that the pharmacy does not perform batch testing.

The platform's medical team may not know which pharmacy will fill your prescription.

At some platforms, the provider writes the prescription and the platform's fulfillment team routes it to whichever pharmacy has capacity that week. The provider never sees the pharmacy name. This is operationally efficient but creates a disconnect: the provider is responsible for the prescription, but the platform controls the quality of the source.

Ask your telehealth platform these questions before your first order:

1. Which specific pharmacy will fill my prescription?
2. Is that pharmacy PCAB-accredited?
3. Can you provide the pharmacy's most recent state inspection report?
4. Will you provide a certificate of analysis for my batch?
5. If you rotate pharmacies, will you notify me before switching?

Platforms that answer transparently earn trust. Platforms that deflect or refuse are hiding something.

State-by-state variation: where telemedicine restrictions complicate access

Telemedicine regulations vary by state, and some states impose restrictions that make telehealth access to compounded tirzepatide slower or impossible.

States that require an initial in-person visit before telemedicine prescribing:

As of April 2026, the following states require at least one in-person visit before a provider can prescribe controlled or high-risk medications via telemedicine: Arkansas, Idaho, Oklahoma, South Dakota, and Texas (for Schedule II-IV controlled substances; GLP-1 medications are not scheduled, so this does not apply, but some Texas providers interpret the rule conservatively and require in-person visits anyway).

For compounded tirzepatide specifically, most of these states do not enforce the in-person requirement because tirzepatide is not a controlled substance. However, some telehealth platforms choose not to operate in these states to avoid regulatory ambiguity.

States that restrict out-of-state telemedicine providers:

Some states require that the prescribing provider hold an active medical license in the state where the patient is located. This is the majority rule, but enforcement varies.

Telehealth platforms handle this by employing providers licensed in all 50 states, or by limiting service to states where their providers are licensed. Before signing up, confirm that the platform has a provider licensed in your state.

States with compounding pharmacy restrictions:

A few states impose additional restrictions on compounding pharmacies that ship into the state. For example, California requires out-of-state compounding pharmacies to register with the California Board of Pharmacy before shipping sterile compounded medications to California residents. Most large compounding pharmacies comply, but smaller ones may not.

If you live in California, New York, or Texas (the three states with the strictest compounding pharmacy regulations), verify that the pharmacy filling your prescription is registered in your state. The telehealth platform should confirm this before processing your order.

States where FormBlends currently operates:

FormBlends operates in 48 states. We do not currently serve patients in Louisiana or West Virginia due to telemedicine licensing restrictions that our provider network has not yet met. We are working toward full 50-state coverage in 2026.

Cost comparison: telehealth vs traditional provider pathways

Compounded tirzepatide is not covered by insurance, regardless of access pathway. The cost is cash-pay. However, the total cost differs depending on which pathway you use.

Telehealth platform (e.g., FormBlends):

• Provider consultation: $0 to $49 (most platforms include this in the medication cost)
• Medication cost: $250 to $450 per month depending on dose and platform
• Shipping: $0 to $15
• Supplies (syringes, alcohol wipes, sharps container): Included or $10 to $20
• Total monthly cost: $250 to $500

Traditional provider referral:

• Provider visit (new patient): $150 to $300 (may be covered by insurance if coded as obesity or diabetes management)
• Provider visit (follow-up): $75 to $150 per visit
• Medication cost: $250 to $400 per month (pharmacy-dependent)
• Shipping: $0 if local pickup, $10 to $20 if shipped
• Supplies: $10 to $30 (purchased separately)
• Total monthly cost: $335 to $600 first month, $260 to $450 ongoing

Direct pharmacy consultation:

• Pharmacy consultation fee: $50 to $150
• Medication cost: $250 to $400 per month
• Shipping or pickup: $0 to $20
• Supplies: $10 to $30
• Total monthly cost: $310 to $600 first month, $260 to $450 ongoing

The telehealth pathway is typically the lowest total cost and the most predictable. Traditional provider pathways cost more upfront due to office visit fees, but some patients value the continuity of care and the ability to use insurance for the visit itself (even though the medication is cash-pay).

The dose matters. Tirzepatide is typically dosed as follows:

• Starting dose: 2.5 mg weekly
• Escalation: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly
• Maintenance dose: 10 to 15 mg weekly for most patients

Higher doses cost more. A 2.5 mg dose might cost $250 per month; a 15 mg dose might cost $450 per month. Telehealth platforms typically price by dose tier. Traditional pharmacies may offer volume discounts for larger vial sizes.

The FormBlends access model: how our pharmacy vetting works

FormBlends partners exclusively with PCAB-accredited 503B outsourcing facilities that meet the following standards:

1. PCAB accreditation with current certificate. We verify accreditation annually and require proof of unannounced inspection passage.

1. Sterility and endotoxin testing on every batch. Our partner pharmacies perform USP <71> sterility testing and USP <85> endotoxin testing on 100% of batches. We receive certificates of analysis for every batch shipped to our patients.

1. Potency testing via HPLC. Every batch undergoes high-performance liquid chromatography (HPLC) assay to verify that the tirzepatide concentration matches the label claim within 5%.

1. FDA-registered API suppliers. Our pharmacies source tirzepatide API exclusively from FDA-registered suppliers that provide certificates of analysis confirming identity, purity, and potency.

1. Clean FDA inspection history. We do not partner with pharmacies that have received FDA warning letters or 483 observation reports with serious deficiencies in the past 36 months.

1. Transparent batch tracking. Every vial shipped to a FormBlends patient includes a lot number. Patients can request the certificate of analysis for their specific lot at any time via the patient portal.

We publish the names of our partner pharmacies in the patient portal (visible after account creation). We do not rotate pharmacies without patient notification. If we add or change a pharmacy partner, we notify active patients at least 30 days in advance.

This is the standard we believe every telehealth platform should meet. It is not universal in the industry.

When compounding becomes illegal: the FDA shortage list question

The legality of compounded tirzepatide depends entirely on the FDA drug shortage list. The moment the FDA removes tirzepatide from the shortage database, compounding becomes illegal under federal law except in extremely narrow circumstances.

The FDA removes drugs from the shortage list when the manufacturer reports that supply has returned to normal levels and can meet demand. For tirzepatide, this depends on Eli Lilly's manufacturing capacity expansion.

Eli Lilly has publicly stated that new manufacturing lines for tirzepatide will come online in Q3 2026. If those lines resolve the shortage, the FDA could remove tirzepatide from the shortage list as early as Q4 2026.

What happens when tirzepatide is removed from the shortage list:

1. Compounding pharmacies must stop accepting new prescriptions immediately. Federal law prohibits compounding of commercially available drugs except when medically necessary (patient allergy to an inactive ingredient, required dose not commercially available, etc.). The prescriber must document the medical necessity in writing.

1. Existing prescriptions can be refilled for a limited time. The FDA typically allows a 60-day wind-down period for patients on existing therapy. After that, patients must transition to brand-name Mounjaro or Zepbound, or discontinue treatment.

1. Telehealth platforms must transition patients or discharge them. Platforms like FormBlends will work with patients to transition to brand-name products (if insurance covers them) or taper off treatment. Some patients will lose access entirely if they cannot afford brand-name pricing ($1,000+ per month without insurance).

This is the single biggest risk in the compounded tirzepatide market. The access window is temporary. The FDA has not announced a timeline for shortage resolution, but the risk is real and growing.

FormBlends monitors the FDA shortage database daily. If tirzepatide is removed, we will notify all active patients within 24 hours and provide a transition plan. Most platforms do not have a formal transition protocol. Ask your platform what their plan is before you start treatment.

Insurance coverage reality check

Compounded tirzepatide is not covered by insurance. This is true across all pathways (telehealth, traditional provider, direct pharmacy). Insurance companies do not reimburse for compounded medications except in rare cases where the FDA-approved version is unavailable and the patient has a documented medical need.

Some patients ask whether they can submit a claim for compounded tirzepatide under their prescription drug benefit. The answer is no. Compounded medications are excluded from Medicare Part D, Medicaid, and private insurance formularies.

However, the provider visit itself may be covered by insurance if the visit is coded as obesity management (ICD-10 code E66.9) or type 2 diabetes management (ICD-10 code E11.9). This applies only to traditional provider pathways, not telehealth platforms that bundle the provider visit into the medication cost.

If you are using the traditional provider pathway, ask your provider to code the visit as obesity or diabetes management and submit it to your insurance. The visit may be covered even though the medication is not. This can reduce your total out-of-pocket cost by $75 to $150 per visit.

Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) is covered by some insurance plans, but coverage is inconsistent. As of April 2026:

• Medicare Part D: Does not cover weight-loss medications, including Zepbound. Covers Mounjaro for type 2 diabetes only if prior authorization is approved.
• Medicaid: Coverage varies by state. About 15 states cover Zepbound for obesity as of April 2026. Most cover Mounjaro for diabetes.
• Private insurance: Coverage depends on the plan. High-deductible plans rarely cover weight-loss medications. Employer-sponsored plans with obesity benefits may cover Zepbound with prior authorization.

If your insurance covers brand-name tirzepatide, the copay is typically $25 to $50 per month with the manufacturer's savings card (Lilly offers a savings card that reduces copays to $25 for commercially insured patients). Without the savings card, copays range from $200 to $600 per month depending on the plan.

If your insurance does not cover brand-name tirzepatide, compounded tirzepatide is the only affordable option for most patients. The cost difference is significant: $250 to $450 per month for compounded vs $1,000+ per month for brand-name without insurance.

The coming regulatory shift: what changes in 2027

The regulatory environment for compounded tirzepatide will change significantly in 2027. Three developments are likely:

1. FDA shortage list removal (probable Q4 2026 or Q1 2027)

As discussed above, Eli Lilly's manufacturing expansion is expected to resolve the tirzepatide shortage by late 2026. If the shortage is resolved, the FDA will remove tirzepatide from the shortage list, and compounding will become illegal except in narrow medical-necessity cases.

The timeline is uncertain. The FDA does not announce shortage removals in advance. The change will happen suddenly, with little warning for patients or platforms.

2. Increased FDA enforcement against non-compliant compounding pharmacies (ongoing)

The FDA has increased inspections of compounding pharmacies since 2023, particularly 503A pharmacies that compound high-volume GLP-1 medications. The agency has issued warning letters to pharmacies with serious sterility deficiencies, improper cleanroom practices, and lack of testing.

Expect this trend to continue. Pharmacies that do not meet USP <797> sterility standards will face enforcement actions. Some will shut down. Others will improve practices to avoid penalties.

For patients, this means the range of pharmacy quality will narrow. The worst actors will be forced out. The remaining pharmacies will meet higher standards. This is good for patient safety but may reduce supply and increase costs.

3. State-level restrictions on telehealth prescribing of compounded medications (possible)

Some state legislatures are considering bills that would restrict telehealth prescribing of compounded weight-loss medications. The concern is patient safety: legislators worry that patients are accessing compounded medications without adequate medical oversight.

As of April 2026, no state has passed such a law. However, bills have been introduced in Florida, Georgia, and Tennessee. If passed, these laws would require an in-person visit before a provider can prescribe compounded tirzepatide via telemedicine.

FormBlends and other telehealth platforms are monitoring these legislative efforts closely. If state restrictions pass, we will adjust our model to comply (e.g., by partnering with local providers who can conduct in-person visits).

The regulatory landscape is shifting. The window for compounded tirzepatide access is open now but may narrow in 2027. Patients who want access should start treatment in 2026 while the pathway is clear.

FAQ

Where can I legally get compounded tirzepatide?

You can legally obtain compounded tirzepatide through a prescription from a licensed provider sent to a state-licensed 503A compounding pharmacy or a federally-registered 503B outsourcing facility. The three pathways are telehealth platforms, direct pharmacy consultation, or referral from your existing provider. All require a valid prescription and patient-provider relationship.

Is compounded tirzepatide the same as Mounjaro or Zepbound?

No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not FDA-approved and has not undergone the same testing and review as brand-name Mounjaro or Zepbound. Compounded medications are prepared by individual pharmacies and are not interchangeable with FDA-approved drugs.

Do I need a prescription for compounded tirzepatide?

Yes. Compounded tirzepatide is a prescription medication. You cannot legally obtain it without a valid prescription from a licensed provider who has established a patient-provider relationship with you. Any website offering compounded tirzepatide without a prescription is operating illegally.

How much does compounded tirzepatide cost?

Compounded tirzepatide costs $250 to $450 per month depending on dose and source. Starting doses (2.5 mg weekly) are at the lower end. Maintenance doses (10 to 15 mg weekly) are at the higher end. This is cash-pay; insurance does not cover compounded medications.

Is compounded tirzepatide covered by insurance?

No. Compounded medications are not covered by Medicare, Medicaid, or private insurance except in rare cases where the FDA-approved version is unavailable and the patient has a documented medical need. Compounded tirzepatide is cash-pay across all access pathways.

How do I know if a compounding pharmacy is safe?

Verify that the pharmacy is PCAB-accredited, performs sterility and endotoxin testing on every batch, sources API from FDA-registered suppliers, and has a clean state inspection history. Ask for a certificate of analysis for your specific batch. Pharmacies that meet these standards are safe. Pharmacies that refuse to answer these questions are not.

Can I get compounded tirzepatide from an online pharmacy?

Only if the online pharmacy is a state-licensed compounding pharmacy or federally-registered 503B facility, and only with a valid prescription. Many websites claiming to sell compounded tirzepatide are not licensed pharmacies and are operating illegally. Verify the pharmacy's license with the state board of pharmacy before ordering.

What is the difference between 503A and 503B compounding pharmacies?

503A pharmacies are state-licensed and regulated by state boards of pharmacy. They can only compound patient-specific prescriptions. 503B outsourcing facilities are federally-registered and regulated by the FDA. They can compound larger batches and must meet cGMP manufacturing standards. Both are legal sources for compounded tirzepatide, but 503B facilities typically have stricter quality controls.

How long will compounded tirzepatide be available?

Compounded tirzepatide is legal as long as tirzepatide remains on the FDA drug shortage list. The shortage is expected to be resolved by late 2026 or early 2027 when Eli Lilly's manufacturing expansion is complete. Once the FDA removes tirzepatide from the shortage list, compounding will become illegal except in narrow medical-necessity cases.

Can my doctor prescribe compounded tirzepatide?

Yes, if your doctor is licensed in your state and willing to write the prescription. Many primary care physicians and endocrinologists are unfamiliar with compounding pharmacies and may be hesitant. You may need to research and suggest a compounding pharmacy yourself. Telehealth platforms simplify this by connecting you with providers who are already familiar with compounded tirzepatide.

What happens if the FDA removes tirzepatide from the shortage list?

Compounding pharmacies must stop accepting new prescriptions immediately. Existing prescriptions can typically be refilled for 60 days while patients transition to brand-name Mounjaro or Zepbound. Patients who cannot afford brand-name pricing may lose access entirely. Telehealth platforms should have a transition plan in place.

Is compounded tirzepatide safe?

Compounded tirzepatide from a PCAB-accredited pharmacy that performs sterility testing and sources API from FDA-registered suppliers is generally safe. However, compounded medications carry more risk than FDA-approved drugs because they are not subject to the same manufacturing oversight. The safety depends entirely on the quality standards of the specific pharmacy preparing your medication.

Can I use a GoodRx coupon for compounded tirzepatide?

No. GoodRx and similar discount programs apply only to FDA-approved medications dispensed by retail pharmacies. Compounded medications are not eligible for GoodRx coupons or any prescription discount programs.

Do telehealth platforms provide the same quality as traditional pharmacies?

It depends on which pharmacy the telehealth platform uses. Some telehealth platforms partner with PCAB-accredited 503B facilities that meet the highest quality standards. Others use 503A pharmacies with minimal oversight. Ask the platform which specific pharmacy will fill your prescription and verify the pharmacy's accreditation and testing protocols before ordering.

What should I do if I experience side effects from compounded tirzepatide?

Contact your prescribing provider immediately. Common side effects (nausea, diarrhea, constipation) are usually manageable with dose adjustment or dietary changes. Serious side effects (severe abdominal pain, vomiting blood, difficulty swallowing) require emergency care. Report all adverse events to the FDA MedWatch program at fda.gov/medwatch.

Sources

1. FDA Drug Shortages Database. Accessed April 2026. accessdata.fda.gov/scripts/drugshortages
2. Drug Quality and Security Act, Public Law 113-54 (2013). Section 503A and 503B.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
4. FDA Inspection Analysis of Compounding Pharmacies. Federal Register. 2023;88:FR-2023-15482.
5. United States Pharmacopeia Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. 2023 revision.
6. United States Pharmacopeia Chapter <71>: Sterility Tests. 2023.
7. United States Pharmacopeia Chapter <85>: Bacterial Endotoxins Test. 2023.
8. National Association of Boards of Pharmacy. Compounding Pharmacy Quality Survey. 2025.
9. Pharmacy Compounding Accreditation Board. Accreditation Standards. 2025. pcab.org
10. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2024.
11. Eli Lilly and Company. Manufacturing Capacity Expansion Announcement. Press release, January 2026.
12. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Exclusions. 2026.
13. State Telemedicine Legislation Database. Federation of State Medical Boards. 2026.
14. FDA Warning Letters to Compounding Pharmacies. fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy or federally-registered 503B outsourcing facility in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.